Results 221 to 230 of about 143,935 (260)
Some of the next articles are maybe not open access.
Blood, 2014
In this issue of Blood , Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 7+3 in older patients with acute myeloid leukemia (AML).[1][1] ![Figure][2] Results of CPX ...
Joshua F, Zeidner, Judith E, Karp
openaire +2 more sources
In this issue of Blood , Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 7+3 in older patients with acute myeloid leukemia (AML).[1][1] ![Figure][2] Results of CPX ...
Joshua F, Zeidner, Judith E, Karp
openaire +2 more sources
Clinical Lymphoma Myeloma and Leukemia, 2020
The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine ...
Kapil, Saxena +3 more
openaire +2 more sources
The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine ...
Kapil, Saxena +3 more
openaire +2 more sources
Blood, 2018
In this issue of Blood , Herrmann et al 1 have developed a novel checkpoint inhibitory T-cell–engaging (CiTE) antibody for acute myeloid leukemia (AML) by fusing the extracellular domain of programmed cell death protein 1 (PD-1 ex ) to a CD3 × CD33 bispecific T-cell engager (BiTE; see figure panels A-B). Incorporation of the PD-1 ex domain increased
Michael P, Rettig, John F, DiPersio
openaire +2 more sources
In this issue of Blood , Herrmann et al 1 have developed a novel checkpoint inhibitory T-cell–engaging (CiTE) antibody for acute myeloid leukemia (AML) by fusing the extracellular domain of programmed cell death protein 1 (PD-1 ex ) to a CD3 × CD33 bispecific T-cell engager (BiTE; see figure panels A-B). Incorporation of the PD-1 ex domain increased
Michael P, Rettig, John F, DiPersio
openaire +2 more sources
Cytotherapy, 2002
BMT is a potentially curative treatment for patients with most forms of myeloid leukemia, such as AML and CML. Cure rates are 50‐80% for patients with leukemia given an allogeneic BMT from a related donor, such as a brother or sister. The pre-transplant conditioning regimen reduces the number of leukemia cells in the recipient, however, it is the donor’
openaire +2 more sources
BMT is a potentially curative treatment for patients with most forms of myeloid leukemia, such as AML and CML. Cure rates are 50‐80% for patients with leukemia given an allogeneic BMT from a related donor, such as a brother or sister. The pre-transplant conditioning regimen reduces the number of leukemia cells in the recipient, however, it is the donor’
openaire +2 more sources
Blood, 2016
In this issue of Blood , Dany et al demonstrate a critical role of the ceramide-regulated signaling pathway in inducing mitophagy to cause cell death and overcome drug resistance of acute myeloid leukemia (AML) cells carrying internal tandem duplication (ITD) of the Fms-like tyrosine kinase 3 (FLT3) gene.
openaire +2 more sources
In this issue of Blood , Dany et al demonstrate a critical role of the ceramide-regulated signaling pathway in inducing mitophagy to cause cell death and overcome drug resistance of acute myeloid leukemia (AML) cells carrying internal tandem duplication (ITD) of the Fms-like tyrosine kinase 3 (FLT3) gene.
openaire +2 more sources
A review of treatment options employed in relapsed/refractory AML
Hematology, 2023Mohamed Zakee Mohamed Jiffry
exaly
Targeting LSD1 for acute myeloid leukemia (AML) treatment
Pharmacological Research, 2021Yongfang Yao, Bin Yu, Menghan Liu
exaly
2009
Several, acquired, non-random chromosomal deletions have been characterized in acute myelogenous leukemia (AML). While the deletion limits vary among patients, there are consistent regions of overlap among the deleted segments between patients. Furthermore, chromosomal deletions are achieved frequently by unbalanced translocations between two and more ...
openaire +2 more sources
Several, acquired, non-random chromosomal deletions have been characterized in acute myelogenous leukemia (AML). While the deletion limits vary among patients, there are consistent regions of overlap among the deleted segments between patients. Furthermore, chromosomal deletions are achieved frequently by unbalanced translocations between two and more ...
openaire +2 more sources